Daily pill could offer alternative to insulin injections for diabetes patients at cardiovascular risk
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and published in The Lancet shows that, for people with type 2 diabetes at increased cardiovascular risk, a daily orforglipron pill had cardiovascular safety comparable to daily insulin glargine injections while providing greater improvements in weight and…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Elevated C-reactive protein linked to increased risk for incident heart failure, all-cause mortality
United Kingdom
-
Supporting adolescent mothers in sub-Saharan Africa means supporting two generations at once
United Kingdom
-
Real-world findings suggest GLP-1 drugs offer health benefits for young people with diabetes
United Kingdom
-
Mauritius is the first country to show it is reversing the type 2 diabetes epidemic using gold-standard testing
United Kingdom
-
Nail detachment over four times more common among GLP-1 users, first controlled study finds
United Kingdom
-
Trevogrumab (anti-myostatin) can help preserve lean mass during and after semaglutide-induced weight loss
United Kingdom
-
Placental health in late pregnancy linked to childhood ADHD
United Kingdom
-
Serum 25(OH)D may serve as a biomarker of disease activity in IBD
United Kingdom